Boehringer registers Phase III survodutide trial in type 2 diabetes

Boehringer Ingelheim's main update is a new Phase III trial registration for survodutide in type 2 diabetes.

• Survodutide (BI 456906), Phase III, type 2 diabetes: Trial NCT07754461 is listed as recruiting, with an actual start date of August 24, 2026. The study is designed to evaluate efficacy and safety of survodutide compared with placebo in participants with type 2 diabetes, as an adjunct to diet and physical activity alone or in combination with either oral antidiabetic medications or insulin.¹ It plans to enroll 600 participants¹ across three parts based on background therapy, and the primary outcome is absolute change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline to Week 41.¹ Participants are expected to remain in the study for about 1 year and 2 months¹, with estimated primary completion on January 17, 2028 and study completion on May 1, 2028.